---
figid: PMC8150754__pharmaceuticals-14-00455-g002
figtitle: 'Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From
  Negative to Positive'
organisms:
- Homo sapiens
- Mus musculus
- Phleum pratense
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC8150754
filename: pharmaceuticals-14-00455-g002.jpg
figlink: /pmc/articles/PMC8150754/figure/pharmaceuticals-14-00455-f002/
number: F2
caption: Targeted and immunotherapies in TNBC clinical studies. Several targeted drugs
  in the TNBC tumor and immune compartments have been explored either with a single
  agent or combinations to attack the tumor-microenvironment. Various signaling targets
  (including the PI3K-AKT-mTOR pathway; Wnt-beta-catenin pathway), DNA damage response
  pathway (targeting PARP), critical/relevant immune checkpoint pathway (PD-L1-PD-1
  axis, CTLA4), angiogenic pathway (HIF1 alpha-VEGF), and ADC target (TROP2-mediated
  ADC) are shown. The molecular landscape of TNBC (including immune compartment) confers
  insight into the novel and investigational targeted therapies, which are directly
  confronting its heterogeneous biology, cellular signaling pathways, and their importance
  for targeting in TNBC tumor. This molecular landscape provides insight into the
  heterogeneous biology and rationale for targeted therapies. AR, androgen receptor;
  RED, FDA approved drugs; BLUE, FDA non-approved drugs but active in clinical trials.
papertitle: 'Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers:
  From Negative to Positive.'
reftext: Dey Nandini, et al. Pharmaceuticals (Basel). 2021 May;14(5):455.
year: '2021'
doi: 10.3390/ph14050455
journal_title: Pharmaceuticals
journal_nlm_ta: Pharmaceuticals (Basel)
publisher_name: MDPI
keywords: triple-negative breast cancer (TNBC) | targeted therapy | immunotherapy
automl_pathway: 0.9400209
figid_alias: PMC8150754__F2
figtype: Figure
redirect_from: /figures/PMC8150754__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8150754__pharmaceuticals-14-00455-g002.html
  '@type': Dataset
  description: Targeted and immunotherapies in TNBC clinical studies. Several targeted
    drugs in the TNBC tumor and immune compartments have been explored either with
    a single agent or combinations to attack the tumor-microenvironment. Various signaling
    targets (including the PI3K-AKT-mTOR pathway; Wnt-beta-catenin pathway), DNA damage
    response pathway (targeting PARP), critical/relevant immune checkpoint pathway
    (PD-L1-PD-1 axis, CTLA4), angiogenic pathway (HIF1 alpha-VEGF), and ADC target
    (TROP2-mediated ADC) are shown. The molecular landscape of TNBC (including immune
    compartment) confers insight into the novel and investigational targeted therapies,
    which are directly confronting its heterogeneous biology, cellular signaling pathways,
    and their importance for targeting in TNBC tumor. This molecular landscape provides
    insight into the heterogeneous biology and rationale for targeted therapies. AR,
    androgen receptor; RED, FDA approved drugs; BLUE, FDA non-approved drugs but active
    in clinical trials.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Cd28
  - Trav6-3
  - Ctla4
  - Cd274
  - Rapgef5
  - Pik3r1
  - Pten
  - Hif1a
  - Vegfa
  - Pdk1
  - Pdpk1
  - Akt1
  - Mtor
  - tor
  - Rorc
  - Ar
  - Parp1
  - Tpm2
  - Tacstd2
  - Lrp1
  - Mvp
  - Txlng
  - Fzr1
  - Axin1
  - Apc
  - Gm12892
  - Myc
  - Nol3
  - CD28
  - HLA-C
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - CTLA4
  - CD8A
  - CD8B
  - CD274
  - RAPGEF5
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PTEN
  - HIF1A
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PDK1
  - PDPK1
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - RORC
  - AR
  - PLCG1
  - PLCG2
  - PARP1
  - COL11A2
  - PARP2
  - PARP3
  - PARP4
  - PARP6
  - PARP8
  - PARP9
  - PARP10
  - PARP11
  - PARP12
  - PARP14
  - PARP15
  - PARP16
  - TNKS
  - TNKS2
  - TIPARP
  - TACSTD2
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - RPSA
  - LRP1
  - PTPRA
  - MVP
  - HNF4A
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - FZR1
  - AXIN1
  - AXIN2
  - APC
  - PROC
  - CSNK1A1
  - KRT1
  - CSNK1A1L
  - MMP1
  - MMP2
  - MMP3
  - MMP7
  - MMP8
  - MMP9
  - MMP10
  - MMP11
  - MMP12
  - MMP13
  - MMP14
  - MMP15
  - MMP16
  - MMP17
  - MMP19
  - MMP20
  - MMP21
  - MMP23B
  - MMP24
  - MMP25
  - MMP26
  - MMP27
  - MMP28
  - MYC
  - Mhc
  - zip
  - Tcr
  - ato
  - gfr
  - nac
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - sima
  - Pvf1
  - Pvf2
  - Pvf3
  - Pvr
  - Akt
  - Tor
  - Egfr
  - ar
  - sl
  - Parp
  - ca
  - inaC
  - Pkc98E
  - aPKC
  - Pkc53E
  - MKP-4
  - p38b
  - rl
  - arr
  - arm
  - pan
  - Wnt5
  - Wnt4
  - wg
  - Wnt2
  - fzr
  - Axn
  - Apc2
  - Fs(3)Apc
  - CkIalpha
  - gish
  - CycE
  - cyc
  - Mmp1
  - 'On'
---
